


## Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

# Effect of High-Dose Vitamin D<sub>3</sub> on Hospital Length of Stay in Critically Ill Patients With Vitamin D Deficiency

## The VITdAL-ICU Randomized Clinical Trial

Karin Amrein, MD, MSc; Christian Schnedl, MD; Alexander Holl, MD; Regina Riedl, MSc; Kenneth B. Christopher, MD; Christoph Pachler, MD; Tadeja Urbanic Purkart, MD; Andreas Waltensdorfer, MD; Andreas Münch, MD; Helga Warnkross, MD; Tatjana Stojakovic, MD; Egbert Bisping, MD; Wolfgang Toller, MD; Karl-Heinz Smolle, MD; Andrea Berghold, PhD; Thomas R. Pieber, MD; Harald Dobnig, MD

 Supplemental content at [jama.com](http://jama.com)

**IMPORTANCE** Low vitamin D status is linked to increased mortality and morbidity in patients who are critically ill. It is unknown if this association is causal.

**OBJECTIVE** To investigate whether a vitamin D<sub>3</sub> treatment regimen intended to restore and maintain normal vitamin D status over 6 months is of health benefit for patients in ICUs.

**DESIGN, SETTING, AND PARTICIPANTS** A randomized double-blind, placebo-controlled, single-center trial, conducted from May 2010 through September 2012 at 5 ICUs that included a medical and surgical population of 492 critically ill adult white patients with vitamin D deficiency ( $\leq 20$  ng/mL) assigned to receive either vitamin D<sub>3</sub> (n = 249) or a placebo (n = 243).

**INTERVENTIONS** Vitamin D<sub>3</sub> or placebo was given orally or via nasogastric tube once at a dose of 540 000 IU followed by monthly maintenance doses of 90 000 IU for 5 months.

**MAIN OUTCOMES AND MEASURES** The primary outcome was hospital length of stay. Secondary outcomes included, among others, length of ICU stay, the percentage of patients with 25-hydroxyvitamin D levels higher than 30 ng/mL at day 7, hospital mortality, and 6-month mortality. A predefined severe vitamin D deficiency ( $\leq 12$  ng/mL) subgroup analysis was specified before data unblinding and analysis.

**RESULTS** A total of 475 patients were included in the final analysis (237 in the vitamin D<sub>3</sub> group and 238 in the placebo group). The median (IQR) length of hospital stay was not significantly different between groups (20.1 days [IQR, 11.1-33.3] for vitamin D<sub>3</sub> vs 19.3 days [IQR, 11.1-34.9] for placebo;  $P = .98$ ). Hospital mortality and 6-month mortality were also not significantly different (hospital mortality: 28.3% [95% CI, 22.6%-34.5%] for vitamin D<sub>3</sub> vs 35.3% [95% CI, 29.2%-41.7%] for placebo; hazard ratio [HR], 0.81 [95% CI, 0.58-1.11];  $P = .18$ ; 6-month mortality: 35.0% [95% CI, 29.0%-41.5%] for vitamin D<sub>3</sub> vs 42.9% [95% CI, 36.5%-49.4%] for placebo; HR, 0.78 [95% CI, 0.58-1.04];  $P = .09$ ). For the severe vitamin D deficiency subgroup analysis (n = 200), length of hospital stay was not significantly different between the 2 study groups: 20.1 days (IQR, 12.9-39.1) for vitamin D<sub>3</sub> vs 19.0 days (IQR, 11.6-33.8) for placebo. Hospital mortality was significantly lower with 28 deaths among 98 patients (28.6% [95% CI, 19.9%-38.6%]) for vitamin D<sub>3</sub> compared with 47 deaths among 102 patients (46.1% [95% CI, 36.2%-56.2%]) for placebo (HR, 0.56 [95% CI, 0.35-0.90],  $P$  for interaction = .04), but not 6-month mortality (34.7% [95% CI, 25.4%-45.0%] for vitamin D<sub>3</sub> vs 50.0% [95% CI, 39.9%-60.1%] for placebo; HR, 0.60 [95% CI, 0.39-0.93],  $P$  for interaction = .12).

**CONCLUSIONS AND RELEVANCE** Among critically ill patients with vitamin D deficiency, administration of high-dose vitamin D<sub>3</sub> compared with placebo did not reduce hospital length of stay, hospital mortality, or 6-month mortality. Lower hospital mortality was observed in the severe vitamin D deficiency subgroup, but this finding should be considered hypothesis generating and requires further study.

**TRIAL REGISTRATION** [clinicaltrials.gov](http://clinicaltrials.gov) Identifier: NCT01130181

JAMA. doi:10.1001/jama.2014.13204  
Published online September 30, 2014.

long time: 19 days

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Karin Amrein, MD, MSc, Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria (karin.amrein@medunigraz.at).

**Section Editor:** Derek C. Angus, MD, MPH, Associate Editor, JAMA (angusdc@upmc.edu).

Vitamin D deficiency is clearly associated with mortality in noncritically ill populations.<sup>1-3</sup> Recent systematic reviews and meta-analyses came to variable conclusions regarding the role of vitamin D supplementation on different outcomes including mortality.<sup>4-7</sup> However, many of the original trials did not determine baseline 25-hydroxyvitamin D levels or included individuals without deficiency.

Since the first report by Lee et al<sup>8</sup> in 2009, a high prevalence of low vitamin D levels has been confirmed in both adult and pediatric patients who are critically ill.<sup>9</sup> The majority of studies suggest that a low vitamin D status is a significant factor associated with disease severity, mortality, or a shorter survival time in the intensive care unit (ICU).<sup>9</sup> A few studies looked at other clinically relevant outcomes, and some, but not all, reported low vitamin D status to be associated with longer length of ICU or hospital stay<sup>9</sup> and a higher incidence of acute renal failure<sup>10</sup> and sepsis.<sup>11</sup>

In addition to its well-known musculoskeletal effects, vitamin D mediates other “nonclassical” effects on immune, cardiac, and vascular systems.<sup>12</sup> Together with its discussed anti-inflammatory properties and metabolic aspects, the potential pleiotropic effects of vitamin D have received considerable attention among intensivists.<sup>9</sup>

It currently remains unknown whether a low vitamin D status in patients who are critically ill reflects disease severity and a generally poor health status prior to ICU admission, or is an independent contributor to morbidity and mortality.

In our previous single-center, double-blind, randomized, placebo-controlled pilot study in a medical ICU, oral high-dose vitamin D<sub>3</sub> quickly corrected vitamin D deficiency without adverse effects.<sup>13</sup> This study, the Correction of Vitamin D Deficiency in Critically Ill Patients (VITdAL-ICU), was designed to evaluate the efficacy and safety of oral high-dose vitamin D<sub>3</sub> to improve outcomes of critical illness.<sup>14</sup>

## Methods

### Study Design

The justification, study design, and methods have been reported previously.<sup>14</sup> This trial was approved by the institutional ethical committee of the Medical University of Graz and the Austrian Agency for Health and Food Safety. In accordance with national and European Union requirements and the principles of the Declaration of Helsinki,<sup>15</sup> written informed consent was obtained, if possible, directly from the patient or from a legal surrogate. For patients for whom this was not possible (mechanical ventilation, septic encephalopathy, etc), the institutional ethical committee, similar to other states of the European Union, approved the use of a “surrogate consent.” Informed consent was obtained at a later time point when the patient survived and regained mental capacity.

### Eligibility Criteria

The study was conducted at the Medical University of Graz, a large tertiary academic center in the southeast of Austria with 1538 beds including 123 ICU beds. Patients were recruited from

5 ICUs: medical, neurological, cardiothoracic surgery, and 2 mixed-surgery units.

Patients who were 18 years or older, expected to stay in the ICU for 48 hours or more, and found to have a 25-hydroxyvitamin D level of 20 ng/mL (to convert to nmol/L, multiply by 2.496) or lower were eligible for study participation.

### Exclusion Criteria

Patients who met any of the following criteria were not eligible to participate in the trial: severely impaired gastrointestinal function; other trial participation, including previous participation in the pilot trial; pregnant or lactating women; hypercalcemia (total calcium of >10.6 mg/dL or ionized serum calcium of >5.4 mg/dL [to convert both to mmol/L, multiply by 0.25]); tuberculosis; sarcoidosis; nephrolithiasis within the prior year; and patients not deemed suitable for study participation (ie, psychiatric disease, living remotely from the clinic, or prisoner status).

### Randomization and Study Drug Administration

Patients were randomly assigned to either a placebo group or vitamin D<sub>3</sub> group in a 1:1 ratio (Figure 1), using the Randomizer for Clinical Trials tool developed at the Medical University of Graz.<sup>16</sup> The randomization block size was 8 for patients stratified according to ICU type and sex.

Because supplementation dosages of vitamin D of 400 IU/d to 4000 IU/d will not restore 25-hydroxyvitamin D levels in a reasonable time frame in ICU patients,<sup>17</sup> a high loading dose regimen was used in this study. This dose was justified based on the safety findings of previous studies using similar oral vitamin D<sub>3</sub> dosing regimens<sup>18,19</sup> and on data from a small, randomized pilot study involving patients in the ICU.<sup>13</sup>

Patients randomized to the vitamin D<sub>3</sub> group received a loading dose of 540 000 IU of vitamin D<sub>3</sub> dissolved in 45 mL of oleum arachidis (Oleovit D<sub>3</sub> [containing 180 000 IU of vitamin D<sub>3</sub> in 15 mL of oleum arachidis per bottle], Fresenius Kabi) either orally or via feeding tube. Patients randomized to the placebo group received 45 mL of oleum arachidis. The study medication was identical in color, consistency, smell, and taste. It was prepared and labeled at our medical university pharmacy.


Starting at 28 days after ingestion of the study medication, patients received 5 monthly maintenance doses of 90 000 IU of oral vitamin D<sub>3</sub> or respective placebo. All trial participants, investigators, and assessors were unaware of the assigned intervention. Patients of both treatment groups were allowed to receive standard vitamin D supplements via enteral nutrition, parenteral nutrition, or both (approximately 200 IU/d) at the discretion of the treating physician. Patients were requested to refrain from taking other vitamin D preparations.

### Follow-up and Outcomes

We followed up all patients for vital status for 6 months after enrollment. At the 6-month telephone follow-up, the number of patients with falls, fractures, hospital readmissions, as well as respiratory tract infections, Short Form-12 (SF-12) health survey score, and the Eastern Cooperative Oncology Group

all at once  
not over a  
week or so

Figure 1. Flow Diagram of the VITdAL-ICU Trial



(ECOG) performance status score were recorded. At the voluntary 6-month visits at the clinic, various tests were performed additionally (hand grip strength and Timed Up and Go [TUG] test), and bone mineral density was measured at the lumbar spine and femoral neck using a bone densitometer (Lunar iDXA, GE Healthcare). Blood and urine samples were collected on days 0, 3, 7, and 28 and, where feasible, at month 6. Race/ethnicity was either self-determined or designated by a patient representative. The Charlson comorbidity index was used to predict 10-year mortality from 22 comorbid conditions with each assigned a score of 1, 2, 3, or 6. Scores were summed to provide a total score to predict mortality. The Therapeutic Intervention Scoring System (TISS-28) was used to measure the extent of nursing workload. The maximum TISS-28 score is 78 and a higher score indicates a higher nursing workload.

The primary study outcome was length of hospital stay starting from the application of the study drug to either hospital discharge or death of a patient. Based on the literature precedent whereby 25-hydroxyvitamin D levels of lower than 12 ng/mL hallmark an increased risk for rickets, osteomalacia, and decreased fractional calcium absorption,<sup>20</sup> a predefined subgroup analysis of patients with severe vitamin D deficiency was specified. The decision and justification to expand the analysis of the previously published protocol (online November 7, 2012; study protocol in Supplement 1)<sup>14</sup> to this subgroup was made during the Study Blind Review Meeting on December 20, 2012, and included in the statistical analysis

plan (statistical analysis plan in Supplement 1) of February 19, 2013, before any data were analyzed starting with March 2013.

### Data Management

Investigators who were blinded to study group assignments collected data. Only potential study drug-related adverse events (hypercalcemia, hypercalciuria, falls, and fractures) were monitored and recorded through the 6-month follow-up. Blinded safety assessments for 28-day mortality were performed after enrollment of 100, 240, and 360 patients and reviewed by the steering committee.

### Laboratory Analysis

The 25-hydroxyvitamin D levels and 1,25-dihydroxyvitamin D levels were measured by an assay based on chemiluminescence technology (IDS-iSYS, Immunodiagnostic Systems). For 25-hydroxyvitamin D, the assay coefficients of variation for control material were 13.4% at 13 ng/mL, 10% at 31 ng/mL, and 9.4% at 64 ng/mL.<sup>21</sup> The laboratory routinely participates in the Vitamin D External Quality Assessment Scheme (DEQAS) program. Vitamin D deficiency was defined as a 25-hydroxyvitamin D level of 20 ng/mL or lower.<sup>22</sup> One hundred samples of our study were also analyzed from frozen samples (−70°C) by liquid chromatography tandem mass spectrometry (LC-MS/MS). The overall correlation of 25-hydroxyvitamin D measurements between the assay and LC-MS/MS (after subtraction of the C3-epimer fraction measured by LC-MS/MS) was  $R = 0.95$ ;  $P < .001$ .

Table 1. Baseline Characteristics of the Intention-to-Treat Population

	No. (%)	
	Placebo (n = 238)	Vitamin D <sub>3</sub> (n = 237)
Age, mean (SD), y	65.3 (14.0)	63.9 (15.5)
Women <sup>a</sup>	83 (34.9)	83 (35.0)
White race	238 (100)	237 (100)
BMI, mean (SD)	27.1 (5.5)	27.2 (5.0)
Charlson comorbidity index, mean (SD) <sup>b</sup>	3.2 (2.2)	3.0 (2.2)
SAPS II at ICU admission, mean (SD) <sup>c</sup>	34.2 (15.7)	32.4 (15.0)
TISS-28 at study inclusion, mean (SD) <sup>d</sup>	38.0 (8.2)	37.7 (7.6)
Admission diagnosis		
Sepsis	18 (7.6)	19 (8.0)
Cardiovascular	32 (13.4)	28 (11.8)
Neurologic	61 (25.6)	54 (22.8)
Other nonsurgical	36 (15.1)	40 (16.9)
Cardiosurgical	44 (18.5)	45 (19.0)
Trauma	18 (7.6)	23 (9.7)
Other surgical	29 (12.2)	28 (11.8)
Admission ICU <sup>a</sup>		
Cardiosurgical	69 (29.0)	68 (28.7)
Neurological	58 (24.4)	58 (24.5)
Medical	53 (22.3)	52 (21.9)
Mixed surgical, 2 units	58 (24.4)	59 (24.9)
At study inclusion		
eGFR, mean (SD), mL/min/1.73m <sup>2</sup> , <sup>e</sup>	65.1 (33.9)	63.7 (34.1)
Chronic kidney disease stage 5 <sup>f</sup>	10 (4.2)	9 (3.8)
Mechanical ventilation	154 (64.7)	151 (63.7)
Norepinephrine use	126 (52.9)	131 (55.3)

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); eGFR, estimated glomerular filtration rate; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score; TISS-28, Therapeutic Intervention Scoring System.

<sup>a</sup> Criterion for randomization stratification (sex and ICU admission).

<sup>b</sup> The Charlson comorbidity index predicts 10-year mortality from 22 comorbid conditions with each assigned a score of 1, 2, 3, or 6. Scores are summed to provide a total score to predict mortality.

<sup>c</sup> The SAPS II measures the severity of disease for patients admitted to the ICU. The point score is calculated from 12 routine physiological measurements and scores can be 0 to 163 with higher scores indicating higher disease severity.

<sup>d</sup> The TISS-28 measures the extent of nursing workload. The maximum TISS-28 score is 78 and a higher score indicates a higher nursing workload.

<sup>e</sup> The eGFR calculation is based on serum creatinine level, age, sex, and race/ethnicity.

<sup>f</sup> Chronic kidney disease stage 5 refers to severe or end-stage kidney failure with an eGFR of lower than 15.

Regarding accuracy, the assay of 25-hydroxyvitamin D measurements were higher by 2.4 ng/mL at the 12 ng/mL cutoff and by 4 ng/mL at the 20 ng/mL cutoff compared with the LC-MS/MS technology.

### Statistical Analysis

Sample size calculation was performed using the Mann-Whitney test. It was based on 2008 routine data collected by medical and surgical ICUs participating in our trial from pa-

tients who stayed 48 hours or more. A mean length of hospital stay of 14 days with a standard deviation of 7 days was inferred. The effect size of a 2-day shorter hospital stay was set arbitrarily and was delineated as what we decided was the smallest unit of time that would be of benefit to the patient. The number of patients needed for the study was calculated to be 468 at a 2-sided significance level of  $\alpha = .05$  and 80% power. Including a drop-out rate of 5%, 490 patients needed to be randomized.

Analyses were conducted in accordance with the intention-to-treat principle with no imputation for any missing data. There was less than 1% missing data.

For the primary analysis for comparing length of hospital stay between the 2 groups, we used the Mann-Whitney test. Sensitivity analysis considered time to hospital discharge as the survival end point with death as a competing event according to Fine and Gray.<sup>23</sup> For secondary end points, we used a *t* test or the Mann-Whitney test for continuous variables and the  $\chi^2$  or Fisher exact test for categorical variables. Laboratory parameters were analyzed by means of analysis of covariance, taking into account the baseline values.

Kaplan-Meier estimates of survival functions were used and compared with the use of the log-rank test. Hazard ratios (HRs) and corresponding 2-sided 95% CIs were estimated with an unadjusted Cox regression model. The same analysis was performed for the predefined subgroup and extended by a formal test for interaction, including the interaction term between the treatment and the predefined subgroups in the models. Furthermore, Cox regression models were applied adjusting for age, sex, Simplified Acute Physiology Score (SAPS) II, degree of comorbidity, and serum calcium, albumin, procalcitonin, and parathyroid hormone levels at baseline. Colinearity among confounding variables was investigated by correlation analysis and further assessed between these variables using the variance inflation factors (>4) and the tolerance statistic (<0.2). A 2-sided *P* value of less than .05 was considered significant, and no adjustments were made for multiple comparisons. Analyses were performed with SAS, version 9.2 (SAS institute).

## Results

### Patients

Enrollment started in May 2010 and was completed in March 2012, after inclusion of 492 patients. Twelve patients did not receive study medication due to various reasons (Figure 1). Follow-up continued through September 2012. The median time from ICU admission to randomization was 2.1 days; mean (interquartile range [IQR]), 3.0 days (1.1-3.9).

Study enrollment, randomization, and follow-up are shown in Figure 1. Of the 1140 patients who were evaluated for this study, 492 patients were randomized, 480 received the allocated study medication, and 475 were included in the final analyses. Details of baseline demographic and clinical characteristics were comparable in the 2 groups (Table 1). The mean age of the patients was 64.6 years (SD, 14.7), and 65% (309 of

average  
age 65

Table 2. Length of Stay and Mortality Outcomes for the Total and Subgroup Populations

	Total Study Population (N = 475)			Prespecified Subgroup Population					
	Placebo (n = 238)	Vitamin D <sub>3</sub> (n = 237)	P Value	Severe Vitamin D Deficiency <sup>a</sup> (n = 200)			Less-Severe Vitamin D Deficiency <sup>b</sup> (n = 275)		
				Placebo (n = 102)	Vitamin D <sub>3</sub> (n = 98)	P Value	Placebo (n = 136)	Vitamin D <sub>3</sub> (n = 139)	P Value
Length of stay, median (range)									
Hospital, d <sup>c</sup>	19.3 (0.1-154.1)	20.1 (0.2-181)	.98	19.0 (1.0-154.1)	20.1 (0.2-181)	.40	20.5 (0.1-113.9)	20.1 (0.2-133)	.47
ICU, d	10.7 (0.1-154.1)	9.6 (0.2-181)	.38	9.1 (0.8-154.1)	9.7 (0.2-181)	.98	12.3 (0.1-113.9)	9.0 (0.2-127)	.26
Mortality, No. (%)									
ICU	63 (26.5)	54 (22.8)		34 (33.3)	23 (23.5)		29 (21.3)	31 (22.3)	
HR (95% CI)	0.97 (0.67-1.39)		.86	0.70 (0.41-1.19)		.18 <sup>d</sup>	1.32 (0.79-2.20)		.28 <sup>d</sup>
28-d	68 (28.6)	52 (21.9)		37 (36.3)	20 (20.4)		31 (22.8)	32 (23.0)	
HR (95% CI)	0.76 (0.53-1.09)		.14	0.52 (0.30-0.89)		.02 <sup>d</sup>	1.06 (0.64-1.73)		.83 <sup>d</sup>
Hospital	84 (35.3)	67 (28.3)		47 (46.1)	28 (28.6)		37 (27.2)	39 (28.1)	
HR (95% CI)	0.81 (0.58-1.11)		.18	0.56 (0.35-0.90)		.01 <sup>d</sup>	1.12 (0.72-1.77)		.61 <sup>d</sup>
6-mo	102 (42.9)	83 (35.0)		51 (50.0)	34 (34.7)		51 (37.5)	49 (35.3)	
HR (95% CI)	0.78 (0.58-1.04)		.09	0.60 (0.39-0.93)		.02 <sup>d</sup>	0.95 (0.64-1.41)		.81 <sup>d</sup>
Causes of death, No. (%)									
Sepsis	30 (29.4)	26 (31.3)		16 (31.4)	12 (25.3)		14 (27.5)	14 (28.6)	
Cardiovascular	30 (29.4)	24 (28.9)	.99	13 (25.5)	9 (26.5)	.95	17 (33.3)	15 (30.6)	.98
Neurologic	19 (18.6)	14 (16.9)		8 (15.7)	4 (11.8)		11 (21.6)	10 (20.4)	
Other	23 (22.5)	19 (22.9)		14 (27.5)	9 (26.5)		9 (17.6)	10 (20.4)	

Abbreviations: HR, hazard ratio; ICU, intensive care unit.

<sup>a</sup> Defined as 25-hydroxyvitamin D level at study inclusion of 12 ng/mL or lower.

<sup>b</sup> Defined as 25-hydroxyvitamin D level at study inclusion higher than 12 ng/mL.

<sup>c</sup> Primary study end point.

<sup>d</sup> P values for interaction between the 2 subgroups: ICU mortality ( $P = .10$ ), 28-day mortality ( $P = .06$ ), hospital mortality ( $P = .04$ ), 6-month mortality ( $P = .12$ ).

Sepsis was the largest cause of death

the 475 patients) were men. Baseline mean 25-hydroxyvitamin D levels were 13.0 ng/mL (SD, 4.1); median, 13.1 ng/mL (IQR, 9.7-16.6). Two hundred patients (42%) had severe vitamin D deficiency defined as 25-hydroxyvitamin D levels of 12 ng/mL or lower.

Of the patients surviving 28 days, 88.2% (150 of 170 patients) in the placebo group and 85.4% (158 of 185 patients) in the vitamin D<sub>3</sub> group continued monthly oral doses of the study drug. No patient was lost to follow-up, and all participant data were included in the analysis according to the original study group assignments with the exception of 5 patients who withdrew consent.

### Outcomes


The main outcome results are reported in Table 2. For the primary study outcome, length of hospital stay, the vitamin D<sub>3</sub> group was not statistically significantly different from the placebo group: 20.1 days (IQR, 11.1-33.3) for the vitamin D<sub>3</sub> group vs 19.3 days (IQR, 11.1-34.9) for the placebo group,  $P = .98$ . The same was true for length of ICU stay: 9.6 days (IQR, 4.2-17.8) for the vitamin D<sub>3</sub> group vs 10.7 days (IQR, 4.9-21.9) for the placebo group,  $P = .38$ . Treating death as a competing risk did not change our results. Among the patients in the vitamin D<sub>3</sub> group, 28.3% (95% CI, 22.6%-34.5%) died in the hospital compared with 35.3% (95% CI, 29.2%-41.7%) in the placebo group (HR, 0.81 [95% CI, 0.58-1.11],  $P = .18$ ). After 6 months, 35.0% (95% CI, 29.0%-41.5%)

of the patients had died in the vitamin D<sub>3</sub> group and 42.9% (95% CI, 36.5%-49.4%) in the placebo group (HR, 0.78 [95% CI, 0.58-1.04];  $P = .09$ ; Figure 2). There were no statistically significant differences between the 2 patient groups with respect to the causes of death, the severity of disease as reflected by the TISS-28, and the percentage of patients with mechanical ventilation or vasopressor treatment (Table 3).

Likewise, nutritional status, use of insulin or antibiotics, and percentage of blood culture positivity were not significantly different (Table 3). No differences were noted in total serum calcium, serum ionized calcium, serum phosphate, and urinary calcium excretion levels at all time points with the exception of a 0.16 mg/dL increase seen in ionized serum calcium levels in the vitamin D<sub>3</sub> group at 6 months ( $P = .04$ ; Tables 4A and Table 4B). The 1,25-dihydroxyvitamin D levels were significantly higher in the vitamin D<sub>3</sub> group at days 3 and 7 only. Although both groups showed decreases in serum parathyroid hormone levels, this was more pronounced in the vitamin D<sub>3</sub> group. The results on inflammatory markers C-reactive protein (CRP) and procalcitonin, N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) levels, and selected parameters of the blood count, renal, and liver function as well as blood glucose levels are shown in Table 4. In the vitamin D<sub>3</sub> group at day 28, procalcitonin and CRP levels were lower while serum albumin and hemoglobin levels were higher compared with the placebo group (all  $P \leq .05$ ; Tables 4 and Table 5).

In the vitamin D<sub>3</sub> group, 52.0% of the patients had increases in absolute 25-hydroxyvitamin D levels higher than 30 ng/mL at day 7, a percentage that remained nearly unchanged until day 28 (Tables 4 and Table 5).

Figure 2. Survival Within 6 Months After Randomization



Nice

**Predefined Severe and Less-Severe Vitamin D Deficiency Subgroup Analysis**

Baseline characteristics within the 2 subgroups (severe vitamin D deficiency subgroup [25-hydroxyvitamin D levels ≤12 ng/mL] and less-severe vitamin D deficiency subgroup [25-hydroxyvitamin D levels >12 ng/mL]) were not different between vitamin D<sub>3</sub> and placebo groups (eTable 1 and eTable 2 in Supplement 2). In the severe vitamin D deficiency subgroup analysis (n = 200; 42% of the study population), length of hospital or ICU stay was not different between the 2 study groups (median hospital stay: 20.1 days [IQR, 12.9-39.1] for the vitamin D<sub>3</sub> group vs 19.0 days [IQR, 11.6-33.8] for the placebo group, P = .40; and median ICU stay: 9.7 days [IQR, 4.2-17.3] for the vitamin D<sub>3</sub> group vs 9.1 days [IQR, 4.1-20.1] for the placebo group, P = .98). The HR for hospital mortality was 0.56 (95% CI, 0.35-0.90); P for interaction = .04. There were 28 deaths among 98 patients (28.6% [95% CI, 19.9%-38.6%]) in the vitamin D<sub>3</sub> group compared with 47 deaths among 102 patients (46.1% [95% CI, 36.2%-56.2%]) in the placebo group. For 6-month mortality, there were 34 deaths (34.7% [95% CI, 25.4%-45.0%]) in the vitamin D<sub>3</sub> group compared with 51 deaths (50.0% [95% CI, 39.9%-60.1%]) in the placebo group (P for interaction = 0.12; Table 2 and Figure 2). After multivariable adjustment for potential confounders including age, sex, SAPS II, Charlson comorbidity index, serum calcium, albumin, procalcitonin, and parathyroid hormone levels, the HR for hospital mortality in the severe vitamin D deficiency subgroup was 0.51 (95% CI, 0.31-0.84), P = .009; for 6-month mortality, 0.50 (95% CI, 0.31-0.79), P = .003. Although parathyroid hormone baseline level was associated with 6-month mortality, the change in parathyroid hormone levels at day 7 or 28 was not associated with mortality outcome.

In the severe vitamin D deficiency subgroup there were 19 fewer individuals with hospital death among patients treated with vitamin D<sub>3</sub>, with a nonsignificantly smaller proportion of deaths related to sepsis and cardiovascular and neurological causes (Table 2). No significant differences were observed in other outcome parameters (Table 3). For the severe vitamin D deficiency subgroup, laboratory parameters relating to vitamin D and mineral metabolism as well as to selected inflammatory, renal, liver, and cardiac parameters were not significantly different between the placebo group and the vitamin D<sub>3</sub> group (eTable 3 in Supplement 2). For the less-severe vitamin D deficiency subgroup, serum and urinary calcium indices were also not significantly different at all time points (eTable 4 in Supplement 2).

**6-Month Follow-Up**

At the 6-month follow-up, there were no statistically significant differences between both groups. Patients with severe vitamin D deficiency at baseline did not show any significant changes compared with the placebo group, whereas patients with higher baseline 25-hydroxyvitamin D levels showed significantly improved grip strength of the right hand as well as a better physical component summary score from the SF-12 questionnaire (eTable 5 in Supplement 2).

Table 3. Selected Secondary Outcomes for the Intention-to-Treat and Subgroup Populations

	Intention-to-Treat Population, No. (%) (N = 475)			Prespecified Subgroup Populations, No. (%)					
	Placebo (n = 238)	Vitamin D <sub>3</sub> (n = 237)	P Value	Severe Vitamin D Deficiency <sup>a</sup> (n = 200)			Less-Severe Vitamin D Deficiency <sup>b</sup> (n = 275)		
				Placebo (n = 102)	Vitamin D <sub>3</sub> (n = 98)	P Value	Placebo (n = 136)	Vitamin D <sub>3</sub> (n = 139)	P Value
At day 6									
Insulin use <sup>c</sup>	92 (42.6)	83 (38.3)	.36	39 (43.3)	33 (36.7)	.36	53 (42.1)	50 (39.4)	.66
Daily dose, mean (SD), IU/d	53 (32)	60 (37)	.21	51 (31)	63 (41)	.13	54 (33)	57 (35)	.69
Antibiotics use	166 (78.3)	159 (74.0)	.29	67 (76.1)	68 (77.3)	.86	99 (79.8)	91 (71.7)	.13
At day 7									
TISS-28, mean (SD) <sup>d</sup>	34.9 (8.1)	35.1 (6.9)	.61	34.0 (7.8)	34.3 (8.0)	.94	35.5 (8.4)	35.6 (6.0)	.56
QTC duration, mean (SD), ms <sup>e</sup>	429.7 (43.5)	427.0 (39.4)	.83	434.4 (45.5)	434.9 (39.6)	.92	425.7 (41.8)	422.1 (38.9)	.42
Mechanical ventilation									
Patients	161 (67.7)	159 (67.1)	.90	69 (67.7)	62 (63.3)	.51	92 (67.7)	97 (69.8)	.70
Duration, median (range), h	167 (0.4-2494)	167 (0.5-1898)	.62	147 (0.4-2162)	157 (1.8-1898)	.76	190 (0.5-2494)	167 (0.5-1443)	.31
Tracheotomy	59 (24.8)	44 (18.6)	.10	24 (23.5)	16 (16.3)	.20	35 (25.7)	28 (20.1)	.27
Norepinephrine use	150 (63.0)	148 (62.5)	.90	68 (66.7)	59 (60.2)	.34	82 (60.3)	89 (64.0)	.52
Duration, median (range), h	81 (0.5-940)	79 (1-1368)	.57	75 (2.0-940)	73 (4.0-1368)	.40	84 (0.5-839)	87 (1-1002)	.94
Nutrition									
Enteral	191 (80.3)	188 (79.3)	.80	82 (80.4)	77 (78.6)	.75	109 (80.2)	111 (79.9)	.95
Parenteral	176 (74.0)	180 (76.0)	.62	69 (67.7)	79 (80.6)	.04	107 (78.7)	101 (72.7)	.25
Use of IV vitamin D	139 (58.4)	145 (61.2)	.54	54 (52.9)	61 (62.2)	.18	85 (62.5)	84 (60.4)	.72
Dose, mean (SD), IU/day in the ICU	140 (111)	141 (122)	.84	140 (104)	147 (129)	.91	140 (116)	137 (117)	.84
Blood cultures <sup>f</sup>									
Samples available	85 (35.7)	92 (38.8)	.48	35 (34.3)	39 (39.8)	.42	50 (36.8)	53 (38.1)	.82
Positivity	28 (32.9)	34 (37.0)	.58	7 (20.0)	16 (41.0)	.08	21 (42.0)	18 (34.0)	.40

Abbreviations: ICU, intensive care unit; IV, intravenous; QTC, heart rate corrected by the Bazett formula; TISS-28, Therapeutic Intervention Scoring System.

<sup>a</sup> Defined as 25-hydroxyvitamin D level at study inclusion 12 ng/mL or lower.

<sup>b</sup> Defined as 25-hydroxyvitamin D level at study inclusion higher than 12 ng/mL.

<sup>c</sup> Subcutaneous, intravenous, or both.

<sup>d</sup> The TISS-28 measures the extent of nursing workload. The maximum TISS-28 score is 78 and a higher score indicates a higher nursing workload.

<sup>e</sup> The QT interval is the time from the start of the Q wave to the end of the T wave. It represents the time taken for ventricular depolarization and repolarization.

<sup>f</sup> Results were thoroughly reviewed for clinical validity by 2 specialized physicians otherwise uninvolved in routine care of the study population. Contaminants such as coagulase-negative staphylococcus were not considered as positive results.

## Adverse Events

No serious adverse events were observed. The highest 25-hydroxyvitamin D levels measured were 107 ng/mL on day 7 and 106 ng/mL at month 6. At month 6, 4 of 37 patients (11%) in the vitamin D<sub>3</sub> group had total serum calcium levels of higher than 10.6 mg/dL (as opposed to 1 of 43 patients [2%] in the placebo group) and 8 of 37 patients (22%) had 25-hydroxyvitamin D levels higher than 60 ng/mL. Study drug discontinuation rates were similar in the 2 groups (27 of 185 patients [14.6%] for the vitamin D<sub>3</sub> group and 20 of 170 patients [11.8%] for the placebo group).

We observed 1 patient in the vitamin D<sub>3</sub> group with a total serum calcium level of 12.0 mg/dL and an ionized serum calcium level of 6.0 mg/dL who was found to have primary hyperparathyroidism (normocalcemic at study inclusion). Another patient in the vitamin D<sub>3</sub> group inadvertently ingested the whole remaining study medication (450 000 IU) within the first month, but the patient's follow-up 25-hydroxyvitamin D level never exceeded 69 ng/mL and total serum calcium level

never exceeded 10.4 mg/dL during the remainder of the study. The number of patients with falls was similar in the 2 study groups (27 of 153 patients [17.7%] for the vitamin D<sub>3</sub> group vs 33 of 136 patients [24.3%] for the placebo group, *P* = .17). Two fractures occurred in each group until month 6.

## Discussion

In this double-blind, randomized trial performed at 5 different ICUs of 1 tertiary hospital, administration of high-dose vitamin D<sub>3</sub> compared with placebo did not reduce hospital length of stay, ICU length of stay, hospital mortality, or 6-month mortality among patients with vitamin D deficiency who are critically ill.

Despite adequate power, the results of our primary end point (length of hospital stay) were negative for both the intention-to-treat population as well as the severe vitamin D deficiency subgroup. In the overall cohort, hospital and 6-month

**Table 4. Parameters Related to Vitamin D and Mineral Metabolism of the Intention-to-Treat Population, Baseline, Day 3, and Day 7<sup>a</sup>**

	Baseline		Day 3		P Value <sup>b</sup>	Day 7		P Value <sup>b</sup>
	Placebo	Vitamin D <sub>3</sub>	Placebo	Vitamin D <sub>3</sub>		Placebo	Vitamin D <sub>3</sub>	
25-Hydroxyvitamin D, mean (SD), ng/mL	13.1 (4.3)	13.0 (4.0)	13.9 (5.0)	33.5 (18.7)	<.001	14.5 (5.1)	35.5 (20.6)	<.001
Patients by 25-hydroxyvitamin D level, No. (%)								
≤12	102 (42.9)	98 (41.4)	88 (39.8)	17 (7.7)		67 (33.2)	14 (6.9)	
13-20	136 (57.1)	139 (58.7)	102 (46.2)	43 (19.6)		109 (54)	36 (17.8)	
21-30	0 (0)	0 (0)	31 (14)	50 (22.7)		23 (11.4)	47 (23.3)	
31-60	0 (0)	0 (0)	0 (0)	87 (39.6)		3 (1.5)	79 (39.1)	
>60	0 (0)	0 (0)	0 (0)	23 (10.5)		0 (0)	26 (12.9)	
Total serum calcium, mean (SD), mg/dL	8.20 (0.80)	8.28 (0.80)	8.44 (0.76)	8.44 (0.72)	.73	8.64 (0.80)	8.68 (0.72)	.69
Maximum level	10.8	11.6	10.8	10.8		10.8	11.2	
Patients with total serum calcium level >10.6, No. (%)	1 (0.4)	3 (1)	1 (0.5)	1 (0.5)		2 (1)	2 (1)	
Serum ionized calcium, mean (SD), mg/dL	4.36 (0.28)	4.40 (0.36)	4.40 (0.32)	4.44 (0.32)	.41	4.44 (0.32)	4.48 (0.28)	.23
Maximum level	4.8	6.0	5.2	5.2		5.6	5.6	
Patients with serum ionized calcium level >5.4, No. (%)	0 (0)	2 (0.8)	0 (0)	0 (0)		1 (0.5)	1 (0.5)	
Serum phosphate, mean (SD), mg/dL	3.60 (1.22)	3.61 (1.32)	3.31 (1.05)	3.41 (1.12)	.26	3.25 (1.14)	3.36 (1.01)	.35
Maximum level	9.7	9.0	8.3	7.9		9.6	7.2	
Patients with serum phosphate level >4.5, No. (%)	45 (19)	47 (20)	28 (13)	25 (12)		17 (9)	23 (11)	
1,25-Dihydroxyvitamin D, median (range), pg/mL	10.01 (1.92-83.46)	11.15 (1.15-88.85)	11.54 (1.92-136.92)	28.08 (2.69-187.69)	<.001	9.42 (0.38-79.62)	22.31 (2.69-150.38)	<.001
PTH, median (range), pg/mL	62.1 (13.7-538.6)	60.2 (8.9-379.8)	58.1 (12.0-456.5)	51.5 (13.6-391.3)	.03	53.0 (8.3-486.7)	44.2 (8.9-297.7)	.02
Urinary calcium:creatinine ratio, median (range), mmol	0.3 (0.0-3.4)	0.2 (0.0-4.3)	0.3 (0.0-3.8)	0.2 (0.0-2.6)	.83	0.4 (0.0-3.1)	0.3 (0.0-6.1)	.31
Maximum ratio	3.4	4.3	3.8	2.6		3.1	6.1	
Patients with urinary calcium:creatinine ratio >0.6, upper limit, No. (%)	58 (27)	50 (24)	43 (24)	35 (20)		44 (30)	36 (24)	
Other biochemical parameters, mean (SD)								
C-reactive protein, median (range), mg/L	105 (0.6-419)	109 (0.8-449)	88 (0.7-475)	89 (0.6-412)	.55	55 (0.6-365)	76 (0.6-356)	.29
Procalcitonin, median (range), ng/mL	0.6 (0.0-363)	0.8 (0.0-318)	0.4 (0.0-114)	0.4 (0.0-97)	.23	0.2 (0.0-95)	0.2 (0.0-36)	.21
Leukocytes, ×10 <sup>9</sup> /L	11.2 (5.9)	11.7 (6.2)	10.4 (5.3)	10.7 (5.9)	.94	11.2 (5.1)	11.7 (5.3)	.43
Serum hemoglobin, g/dL	10.2 (1.9)	10.1 (1.7)	10.0 (1.7)	9.9 (1.7)	.94	10.0 (1.8)	10.0 (1.7)	.66
Fibrinogen, mg/dL	465 (186)	470 (195)	551 (175)	537 (191)	.36	556 (171)	549 (177)	.65
Serum creatinine, mg/dL	1.41 (1.04)	1.48 (1.21)	1.29 (1.06)	1.45 (1.29)	.41	1.21 (0.89)	1.28 (1.24)	.71
Serum bilirubin, median (range), mg/dL	0.7 (0.1-11.4)	0.7 (0.2-37)	0.6 (0.2-17.0)	0.6 (0.2-39.3)	.81	0.6 (0.1-30.9)	0.6 (0.2-45.8)	.87
NT-proBNP, median (range), g/mL	1883 (18-35 000)	1715 (27-35 000)	2155 (26-35 000)	1595 (8-35 000)	.22	1744 (11-35 000)	1419 (6-35 000)	.81
Blood glucose, mg/dL	151 (52)	153 (52)	130 (39)	130 (36)	.73	131 (51)	126 (37)	.18
Serum albumin, g/dL	2.89 (0.54)	2.83 (0.56)	2.90 (0.53)	2.81 (0.56)	.36	2.99 (0.57)	2.90 (0.59)	.41

failed to restrict Calcium

did not have any cofactors for bone, etc

Abbreviations: NT-proBNP, N-terminal fragment of the prohormone brain-type natriuretic peptide; PTH, parathyroid hormone.

SI conversion factors: To convert total and ionized calcium to mmol/L, multiply by 0.25; 25-hydroxyvitamin D to nmol/L, multiply by 2.496; 1,25-dihydroxyvitamin D to pmol/L, multiply by 2.6.

<sup>a</sup> Blood samples available (No. of patients): baseline (428 for the vitamin D<sub>3</sub>

group and 475 for the placebo group), day 3 (356 for the vitamin D<sub>3</sub> group and 441 for the placebo group), day 7 (299 for the vitamin D<sub>3</sub> group and 404 for the placebo group).

<sup>b</sup> Analysis of covariance for differences between groups at day 3 and day 7, taking into account the baseline values.

mortality rates were numerically lower in the vitamin D<sub>3</sub> group, but these differences were not significant. The absolute difference in the number of survivors at 6 months was 19 for the overall cohort, and of these 17 were in the severe vitamin D deficiency subgroup. However, analysis of the causes of death revealed that the vitamin D<sub>3</sub> group compared with the pla-

cebo group had no differences in the proportions of deaths in all categories (sepsis, cardiovascular, neurologic, and other causes).

In the severe vitamin D deficiency subgroup analysis, there was no significant difference in hospital length of stay between the vitamin D<sub>3</sub> group (20.1 days) and the placebo group



Table 5. Parameters Related to Vitamin D and Mineral Metabolism of the Intention-to-Treat Population, Day 28 and Month 6<sup>a</sup>

	Day 28		P Value <sup>b</sup>	Month 6		P Value <sup>b</sup>
	Placebo	Vitamin D <sub>3</sub>		Placebo	Vitamin D <sub>3</sub>	
25-Hydroxyvitamin D, mean (SD), ng/mL	17.3 (6.9)	32.7 (19.3)	<.001	26.2 (12.8)	46.0 (17.5)	<.001
Patients by 25-hydroxyvitamin D level, No. (%)						
≤12	14 (23.3)	9 (12.5)		5 (11.6)	0 (0)	
13-20	27 (45)	15 (20.8)		9 (20.9)	2 (5.4)	
21-30	17 (28.3)	11 (15.3)		14 (32.6)	2 (5.4)	
31-60	2 (3.3)	31 (43.1)		15 (34.9)	25 (67.6)	
>60	0 (0)	6 (8.3)		0 (0)	8 (21.6)	
Total serum calcium, mean (SD), mg/dL	8.84 (0.68)	9.00 (0.60)	.11	9.56 (0.44)	9.76 (0.68)	.15
Maximum level	10.4	10.4		10.8	12.0	
Patients with total serum calcium level >10.6, No. (%)	0 (0)	0 (0)		1 (2)	4 (11)	
Serum ionized calcium, mean (SD), mg/dL	4.52 (0.28)	4.56 (0.28)	.31	4.60 (0.24)	4.76 (0.28)	.04
Maximum level	5.2	6.0		5.2	6.0	
Patients with serum ionized calcium level >5.4, No. (%)	0 (0)	1 (1.4)		0 (0)	1 (2.7)	
Serum phosphate, mean (SD), mg/dL	3.54 (1.26)	3.55 (0.84)	.85	3.26 (0.52)	3.39 (0.47)	.25
Maximum level	9.1	5.8		4.2	4.2	
Patients with serum phosphate level >4.5, No. (%)	9 (16)	7 (10)		0 (0)	0 (0)	
1,25-Dihydroxyvitamin D, median (range), pg/mL	12.12 (2.69-54.23)	14.81 (2.69-90.00)	.24	35.77 (11.54-88.46)	36.92 (4.23-102.69)	.75
PTH, median (range), pg/mL	38.0 (6.5-450.7)	33.1 (8.7-148.6)	.02	53.6 (15.5-178.5)	40.3 (14.3-161.9)	.09
Urinary calcium:creatinine ratio, median (range), mmol	0.5 (0.0-2.3)	0.7 (0.0-1.9)	.15	0.2 (0.0-0.8)	0.3 (0.0-1.2)	.29
Maximum ratio	2.3	1.9		0.8	1.2	
Patients with urinary calcium:creatinine ratio >0.6, upper limit, No. (%)	18 (40)	25 (51)		2 (5)	4 (11)	
Other biochemical parameters, mean (SD)						
C-reactive protein, median (range), mg/L	51 (0.6-316)	32 (0.6-212)	.04	3.5 (0.6-30)	2.6 (0.6-108)	.32
Procalcitonin, median (range), ng/mL	0.2 (0.0-66)	0.1 (0.0-35)	.05	0.1 (0.0-0.3)	0.1 (0.0-0.5)	.71
Leukocytes, ×10 <sup>9</sup> /L	8.2 (3.9)	9.6 (5.2)	.32	6.9 (3.3)	7.1 (2.6)	.95
Serum hemoglobin, g/dL	10.3 (1.9)	10.8 (1.9)	.05	13.2 (1.6)	13.4 (2.0)	.92
Fibrinogen, mg/dL	459 (156)	438 (158)	.23	354 (105)	363 (109)	.65
Serum creatinine, mg/dL	1.21 (1.01)	1.15 (0.90)	.73	1.03 (0.41)	1.10 (0.39)	.72
Serum bilirubin, median (range), mg/dL	0.5 (0.1-30.4)	0.5 (0.1-10)	.17	0.6 (0.3-4.7)	0.6 (0.2-1.7)	.01
NT-proBNP, median (range), g/mL	1730 (12-35 000)	680 (13-35 000)	.38	140 (12-2109)	164 (15-4874)	.73
Blood glucose, mg/dL	131 (59)	121 (40)	.13	105 (39)	100 (28)	.42
Serum albumin, g/dL	3.13 (0.71)	3.25 (0.69)	.04	4.49 (0.48)	4.45 (0.46)	.73

Abbreviations: NT-proBNP, N-terminal fragment of the prohormone brain-type natriuretic peptide; PTH, parathyroid hormone.

SI conversion factors: To convert total and ionized calcium to mmol/L, multiply by 0.25; 25-hydroxyvitamin D to nmol/L, multiply by 2.496; 1,25-dihydroxyvitamin D to pmol/L, multiply by 2.6.

<sup>a</sup> Blood samples available (No. of patients): day 28 (94 for the vitamin D<sub>3</sub> group and 132 for the placebo group) and month 6 (69 for the vitamin D<sub>3</sub> group and 80 for the placebo group).

<sup>b</sup> Analysis of covariance for differences between groups at day 28 and month 6, taking into account the baseline values.

(19.0 days), although hospital mortality was significantly lower in the vitamin D<sub>3</sub> group (28.6%) compared with the placebo group (46.1%) (HR, 0.56 [95% CI, 0.35-0.90], *P* for interaction = .04), and remained significant with adjustment for potential confounders. The 6-month mortality rates were lower in the vitamin D<sub>3</sub> group (34.7%) compared with the placebo group (50.0%), but the test for interaction was not significant (*P* for interaction = .12).

Reasons to explain the discrepancy between reduced hospital mortality rates and similar length of stay in the severe vitamin D deficiency subgroup include the possibility that vi-

tamin D replacement might decrease the incidence of adverse outcomes in the ICU (eg, nosocomial infections). In such a case, length of stay may remain unchanged and mortality could be expected to be lower in certain disease categories, although there were no significant differences in mortality rates across the death categories examined in our study. In addition, it is possible that in some patients with established diseases, vitamin D<sub>3</sub> treatment may help individuals survive but at the expense of increased length of stay, whereas in other patients, vitamin D<sub>3</sub> treatment might support recovery from disease, potentially leading to a decreased length of stay.

how many who died had low response to vit D?

Patients with less-severe vitamin D deficiency did not exhibit a survival benefit with vitamin D<sub>3</sub> treatment. However, the significantly better hand grip strength and physical performance scale after 6 months suggest a potential benefit in the important recovery and rehabilitation phase. This may be a relevant finding as an increasing number of patients in the ICU survive but develop postintensive care syndrome with significant morbidity and limited treatment options.<sup>24</sup>

In this study, we used a high oral loading dose regimen of vitamin D<sub>3</sub> with the intention to restore adequate 25-hydroxyvitamin D levels within days. Previous experiences in small studies<sup>13,18,19</sup> suggest that such single doses of vitamin D<sub>3</sub> are safe. However, only half of patients treated with vitamin D<sub>3</sub> achieved serum 25-hydroxyvitamin D levels higher than 30 ng/mL. This low percentage of vitamin D<sub>3</sub> responders may have been related to critical illness-associated compromised gastrointestinal function and to renal and drug-related compromises of the hepatic cytochrome P450 (CYP450) system that is implicated in 25-hydroxylation of vitamin D<sub>3</sub>.<sup>25,26</sup>

Our data suggest that the vitamin D<sub>3</sub> dose used in this study was safe. Mild hypercalcemia was the major adverse effect associated with high-dose vitamin D<sub>3</sub>, but no serious adverse events were recorded. Mean calcium and phosphorus levels were similar between the placebo and vitamin D<sub>3</sub> group. Serum ionized calcium levels were somewhat higher in the vitamin D<sub>3</sub> group only at the 6-month follow-up. The 2 highest individual 25-hydroxyvitamin D levels achieved were far from levels considered to be acutely toxic (>150 ng/mL).<sup>12,27</sup> Individual hypercalcemia did occur in some instances in the vitamin D<sub>3</sub> group, but remained asymptomatic and did not require specific treatment. Renal parameters or the degree of hypercalciuria were not different between the groups. Falls and fractures were found to be increased in studies using single, annual high doses of vitamin D<sub>3</sub><sup>28,29</sup> but were not different in our study that in contrast also used a different treatment protocol with monthly maintenance doses of vitamin D<sub>3</sub>.

This study has several limitations. First, we opted for length of stay and not mortality as the primary end point.

The reason for doing so is that when the study was initiated in early 2010, mortality rates were only reported descriptively in 1 observational study of 42 patients.<sup>8</sup> We presumed that whatever positive effects vitamin D<sub>3</sub> supplementation may have could lead to a general improvement in health status and a shorter length of stay. Second, another limitation is related to external validity, in particular, the single-center design and the lack of nonwhite or pediatric patients. This may limit the generalizability of our findings, even though we treated a mixed population of adult patients who were critically ill without restriction of age, sex, or admission diagnosis. Third, the only positive finding favoring vitamin D administration, the decrease in hospital mortality rate in patients with severe vitamin D deficiency, was based on a subgroup analysis and did not constitute a primary end point. Given this, combined with the null overall effect, this finding should be interpreted as hypothesis-generating only. Fourth, our sample size might not allow for the identification of rare adverse effects of high-dose vitamin D<sub>3</sub>; however, this would be of less importance if a clear survival advantage had been confirmed. Fifth, another limitation may have been utilization of an immunoassay for determination of 25-hydroxyvitamin D levels; however this method correlated favorably with the LC-MS/MS method.<sup>30</sup> Sixth, we did not assess hospital infection rates and the analysis was limited to known study drug-specific adverse events.

## Conclusions

Among patients with vitamin D deficiency who are critically ill, administration of high-dose vitamin D<sub>3</sub> compared with placebo did not improve hospital length of stay, hospital mortality, or 6-month mortality. Lower hospital mortality was observed in a subgroup of patients with severe vitamin D deficiency, but this finding should be considered hypothesis generating and requires further study.

did not help everyone - only those who were deficient!!

### ARTICLE INFORMATION

**Published Online:** September 30, 2014.  
doi:10.1001/jama.2014.13204.

**Author Affiliations:** Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Austria (Amrein, Schnedl, Warnkross, Pieber, Dobnig); Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Austria (Holl); Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Austria (Riedl, Berghold); Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Christopher); Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Austria (Pachler, Waltensdorfer, Münch, Toller); Division of General Neurology, Department of Neurology, Medical University of Graz, Austria (Urbanic Purkart); Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria (Stojakovic); Division of Cardiology,

Department of Internal Medicine, Medical University of Graz, Austria (Bisping); Medical Intensive Care Unit, Department of Internal Medicine, Medical University of Graz, Austria (Smolle); Schilddrüsen-Endokrinologie-Osteoporose Institut Dobnig GmbH, Graz, Austria (Dobnig).

**Author Contributions:** Drs Berghold and Riedl had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Amrein, Riedl, Stojakovic, Berghold, Pieber, Dobnig.  
**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Amrein, Schnedl, Riedl, Christopher, Berghold, Pieber, Dobnig.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Riedl, Berghold.

**Obtained funding:** Amrein, Pieber, Dobnig.

**Administrative, technical, or material support:** Amrein, Schnedl, Holl, Pachler, Urbanic Purkart,

Waltensdorfer, Münch, Warnkross, Bisping, Stojakovic, Toller, Smolle, Pieber, Dobnig.  
**Study supervision:** Amrein, Schnedl, Warnkross, Pieber, Dobnig.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Amrein reports receiving lecture fees from Fresenius Kabi. Dr Christopher reports receiving honoraria from the International Symposium on Intensive Care and Emergency Medicine. Dr Pachler reports receiving personal fees from Orion Pharma. Dr Stojakovic reports receiving personal fees from Fresenius Kabi. Dr Dobnig reports receiving lecture fees from Fresenius Kabi. No other disclosures were reported.

**Funder/Sponsor:** The study was supported by the European Society for Clinical Nutrition and Metabolism (ESPEN), a research grant including provision of study medication from Fresenius Kabi (Germany), and the Austrian National Bank (Jubiläumsfonds, Project Nr. 14143).

**Role of the Funder/Sponsor:** The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Previous Presentation:** Selected data of this manuscript were presented at the ICE/ENDO 2014 in Chicago (June 21-24), the 36th ESPEN Congress on Clinical Nutrition and Metabolism in Geneva (September 6-9, 2014), and at LIVES 2014, the 27th ESICM Annual Congress in Barcelona 2014.

**Additional Contributions:** We thank the staff of the participating intensive care units, patients, relatives, family physicians, health care workers in other institutions, and caregivers who made this trial possible. We thank Andrea Grisold, MD, and Thomas Valentin, MD (both from Medical University of Graz, Austria), for validating blood culture results. We also thank Johannes Plank, MD, Harald Sourij, MD, Robert Krause, MD (all from Medical University of Graz, Austria), Steven Amrein, MD (Privatklinik der Kreuzschwester, Graz, Austria), and Chris Wrighton for inspiring suggestions; Bettina Fürpass, Gerit Wünsch, PhD, Andreas Meinitzer, PhD, Hans Peter Dimai, MD (all Medical University of Graz, Austria), and Marianne Schmid, MD (Steiermärkische Gebietskrankenkasse, Graz, Austria), provided invaluable support for the final analyses of this trial. None of these individuals received financial compensation for their contribution to this study.

## REFERENCES

- Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev*. 2011;(7):CD007470.
- Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. *Arch Intern Med*. 2008;168(12):1340-1349.
- Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. *Am J Clin Nutr*. 2012;95(1):91-100.
- Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. *BMJ*. 2014;348:g1903.
- Theodoratou E, Zoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ*. 2014;348:g2035.
- Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. *Lancet Diabetes Endocrinol*. 2014;2(4):307-320.
- Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. *Lancet Diabetes Endocrinol*. 2014;2(1):76-89.
- Lee P, Eisman JA, Center JR. Vitamin D deficiency in critically ill patients. *N Engl J Med*. 2009;360(18):1912-1914.
- Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients. *Inflamm Allergy Drug Targets*. 2013;12(4):273-281.
- Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. *Crit Care Med*. 2012;40(12):3170-3179.
- Moromizato T, Litonjua AA, Braun AB, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. *Crit Care Med*. 2014;42(1):97-107.
- Holick MF. Vitamin D deficiency. *N Engl J Med*. 2007;357(3):266-281.
- Amrein K, Sourij H, Wagner G, et al. Short-term effects of high-dose oral vitamin D<sub>3</sub> in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. *Crit Care*. 2011;15(2):R104.
- Amrein K, Schnedl C, Berghold A, Pieber TR, Dobnig H. Correction of vitamin D deficiency in critically ill patients—VITdAL@ICU study protocol of a double-blind, placebo-controlled randomized clinical trial. *BMC Endocr Disord*. 2012;12(1):27.
- World Medical Association. Declaration of Helsinki—ethical principles for medical research involving human subjects. <http://www.wma.net/en/30publications/10policies/b3/>. Accessed September 1, 2014.
- Medical University of Graz. Randomizer. <http://www.randomizer.at/>. Accessed September 17, 2014.
- McNally JD. Vitamin D as a modifiable risk factor in critical illness: questions and answers provided by observational studies. *J Pediatr (Rio J)*. 2014;90(2):99-101.
- Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR. High-dose oral vitamin D<sub>3</sub> supplementation in the elderly. *Osteoporos Int*. 2009;20(8):1407-1415.
- von Restorff C, Bischoff-Ferrari HA, Theiler R. High-dose oral vitamin D<sub>3</sub> supplementation in rheumatology patients with severe vitamin D<sub>3</sub> deficiency. *Bone*. 2009;45(4):747-749.
- Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: Institute of Medicine; 2011.
- Cluse ZN, Fudge AN, Whiting MJ, McWhinney B, Parkinson I, O'Loughlin PD. Evaluation of 25-hydroxy vitamin D assay on the immunodiagnostic systems iSYS analyser. *Ann Clin Biochem*. 2012;49(Pt 2):159-165.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96(7):1911-1930.
- Fine J, Gray J. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496-509. doi:10.1080/01621459.1999.10474144.
- Mehlhorn J, Freytag A, Schmidt K, et al. Rehabilitation interventions for postintensive care syndrome: a systematic review. *Crit Care Med*. 2014;42(5):1263-1271.
- Spriet I, Meersseman W, de Hoon J, von Winkelmann S, Wilmer A, Willems L. Mini-series: II: clinical aspects: clinically relevant CYP450-mediated drug interactions in the ICU. *Intensive Care Med*. 2009;35(4):603-612.
- Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. *J Am Soc Nephrol*. 2010;21(9):1488-1497.
- Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. *J Nutr*. 2006;136(4):1117-1122.
- Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA*. 2010;303(18):1815-1822.
- Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology (Oxford)*. 2007;46(12):1852-1857.
- Knox S, Harris J, Calton L, Wallace AM. A simple automated solid-phase extraction procedure for measurement of 25-hydroxyvitamin D<sub>3</sub> and D<sub>2</sub> by liquid chromatography-tandem mass spectrometry. *Ann Clin Biochem*. 2009;46(pt 3):226-230.